背景 在化疗后增加filgrastim的剂量进行动员,是否能够提高外周血祖细胞(PBPC)的收集,从而在自体移植后更快造血植入,目前仍未可知。设计和方法 一个随机、开放标记、多中心参与的试验,研究对象为乳腺癌、多发性骨髓瘤和淋巴瘤病人,这些病人在标准化疗后随机接受5或10g/kg/d的filgrastim来动员PBPCs。在高剂量化疗后,从头两次粒细胞单采中获得的成份被回输,所有的病人在移植后均接受了5g/kg/d的fil Background It remains unclear whether increasing the dose of filgrastim after chemotherapy for mobilization will increase the collection of peripheral blood progenitor cells (PBPCs) and allow faster hematopoietic engraftment after autologous transplantation. Design and Methods A randomized, open-label, multicentre trial of breast cancer, multiple myeloma and lymphoma patients who received filgrastim at 5 or 10 g / kg / d after randomized chemotherapy to mobilize PBPCs . After high-dose chemotherapy, the components obtained from the first two granulocyte apheresis were returned and all patients received a fil of 5 g / kg / d after transplantation